HugoScore hugoscore.org

Full review

RTHM CAIHL draft report

Evidence-linked HugoScore draft report for a health AI tool that affects patients.

Back to profile Markdown source

HugoScore CAIHL Draft Report: RTHM

Status: Draft for human review Generated: 2026-06-20 Last reviewed: 2026-06-20 Review method: Deep public-source review of RTHM homepage, staging homepage, support FAQ, medications page, clinic page, treatments page, about page, privacy policy, terms of use, and LegitScript certification checker. No login, app walkthrough, vendor interview, clinician interview, independent model evaluation, or independent outcomes review. Service: RTHM Vendor: RTHM, Inc. Category: Patient care navigation and health copilot AI / complex-care virtual care pathway

Executive Summary

RTHM is a patient-facing intelligence platform and virtual-care pathway for complex chronic conditions, including Long COVID, ME/CFS, POTS, MCAS, hEDS, and related illnesses. The public product gathers health history, symptoms, labs, questionnaires, uploaded records, HIE-retrieved records, and AI chat context to generate a health roadmap, research-informed hypotheses, and testing or treatment suggestions.

From a CAIHL perspective, RTHM is potentially agency-expanding because it gives patients a condition-specific way to organize records, see patterns, prepare questions, and act on complex illness care. The caution is that the same pathway can route patients toward paid medications, labs, and clinic services, while the legal terms permit de-identified data sharing and model or service improvement uses.

Agency posture: Potentially agency-expanding, with vendor-funnel and data-use caveats Confidence: Medium draft, official sources only

Evidence

Mixed HugoScore Profile

  • Who does this AI serve? Patient-directed, with vendor and clinical-service alignment caveats. The intelligence platform is presented for patients and is free to use, but it is integrated with paid medication, lab, and clinic pathways.
  • Can patients tell AI is involved? Yes. Public pages describe AI-powered insights, an AI chat, an AI navigation assistant, and AI-generated roadmap functions.
  • Can patients meaningfully choose? Partial. Use is patient-initiated, and patients can skip HIE retrieval and upload records manually. Paid services are state-limited and may require eligibility, insurance compatibility, or cash payment.
  • Can patients correct or challenge what the AI produces? Partial. Public materials describe account deletion, retaking questionnaires, support contact, bug reports, and chat feedback. App-level roadmap editing, audit, and challenge workflows need verification.
  • Does it help patients understand or act? Yes. Health roadmaps, research updates, shareable insights, appointment-question support, medication requests, lab pathways, and clinic escalation are directly action-oriented.

Patient Agency Interpretation

RTHM's strongest agency value is that it gives patients with complex, often poorly served conditions a structured way to gather data, interpret patterns, and prepare next steps. This can support critical reflection and strategic action.

The main CAIHL concern is alignment. A free intelligence platform can be helpful, but it also sits beside paid medication, lab, and clinic services. The review should watch whether treatment suggestions remain patient-defined, evidence-grounded, and contestable, or whether they become a vendor-controlled care funnel.

Publication Recommendation

Ready for human review as a draft profile.

Before confidence increases, verify app-level controls for roadmap editing, correction, deletion, export, HIE data return, model-training restrictions, clinical escalation, and paid-care routing.